Barrington Lifts PT on Orthofix Medical (OFIX) to $17 From $16, Keeps an Overweight Rating
A surgeon using a bone growth stimulator device in a modern operating theatre.
The analyst told investors in a research note that Orthofix Medical Inc. (NASDAQ:OFIX) reported strong fiscal Q2 results and affirmed its 2025 outlook, supporting the optimistic rating.
Orthofix Medical Inc. (NASDAQ:OFIX) announced its fiscal Q2 2025 results on August 5, reporting net sales of $203.1 million for the quarter, representing a 2% growth on a reported basis and 4% on a pro forma constant currency basis compared to Q2 2024.
U.S. Spine Fixation underwent a net sales growth of 5% and procedure volume growth of 7% compared to the same quarter last year, while Bone Growth Therapies' net sales reached $62.6 million, representing growth of 6%.
Orthofix Medical Inc. (NASDAQ:OFIX) provides medical devices and operates through the Global Spine and Global Extremities business segments. Its Global Spine reporting segment encompasses three primary product categories: Bone Growth Therapies, Spinal Implants, and Biologics.
While we acknowledge the potential of OFIX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Cellebrite Begins Its Next Chapter
Key Points Cellebrite continued to see solid growth in the second quarter of 2025, led by a big jump in free cash flow. The company named interim CEO Tom Hogan to take on the role permanently and also announced a new chief financial officer. Cellebrite is cautiously optimistic about recent acquisition activity and the prospect for further business. 10 stocks we like better than Cellebrite › Here's our initial take on Cellebrite DI's (NASDAQ: CLBT) financial report. Key Metrics Metric Q2 2024 Q2 2025 Change vs. Expectations Total revenue $95.7 million $113.3 million +18% Beat Adjusted earnings per share $0.10 $0.12 +20% Beat Annualized recurring revenue $345.9 million $418.9 million +21% n/a Free cash flow $12.4 million $29.0 million +133% n/a Cellebrite Moves Forward on Multiple Fronts Cellebrite has enjoyed high demand for its digital investigative software, with both government entities and private-sector corporate clients adopting Cellebrite's platform extensively. Revenue for the second quarter was up 18% year over year, and annualized recurring revenue from the software-as-a-service platform climbed at a faster 21% rate. Earnings per share came in a penny better than expected as Cellebrite celebrated rising margins from its effectiveness in controlling costs and making the most of sales growth. A dollar-based net retention rate of 120% signaled that existing clients are making greater use of Cellebrite's services. CEO Tom Hogan pointed to Cellebrite's plans to acquire virtualization technology specialist Corellium and its collaboration with the U.S. Department of Justice as important factors that could expand the scope of its business. The Corellium deal hasn't yet gotten final approval, though, so Cellebrite hasn't incorporated its potential impact into guidance. As for Hogan, the once-interim CEO has formally been named to fill the role permanently. Cellebrite's board chair had kind words to say about Hogan's experience and leadership. Joining Hogan will be David Barter, who will take over the CFO role from the retiring Dana Gerner. Immediate Market Reaction Investors were generally pleased with Cellebrite's news. The stock moved higher by almost 5% in premarket trading during the first 45 minutes after the release of its financial report. Both sales and earnings were higher than most of those following Cellebrite had anticipated, which was likely the biggest contributor to the upward move. Even so, it's important to put the modest move into context. Cellebrite's stock soared during late 2024 and into the beginning of 2025, but since their February peak, the shares had lost roughly half their value at their worst levels. Signs of a rebound are encouraging, though, and Cellebrite hopes that future results will validate investors' confidence. What to Watch Cellebrite's guidance for the third quarter and for the full 2025 year doesn't show a huge acceleration of sales growth. Annualized recurring revenue is likely to rise to between $435 million and $445 million next quarter and to between $460 million and $475 million by year-end. Third-quarter revenue of $121 million to $126 million would be 13% to 18% higher than in the year-ago period. Full-year 2025 sales of $465 million to $475 million would represent growth of 16% to 18%. Those are all solid numbers. However, in some investors' eyes, they don't represent the full potential of Cellebrite's business. We look forward to seeing whether Hogan, in his permanent CEO role, can light a fire under Cellebrite and build further momentum toward a full recovery in the stock. Helpful Resources Full earnings report Investor relations page Should you invest $1,000 in Cellebrite right now? Before you buy stock in Cellebrite, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Cellebrite wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $649,544!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,113,059!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Dan Caplinger has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Cellebrite. The Motley Fool has a disclosure policy. Cellebrite Begins Its Next Chapter was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20 minutes ago
- Yahoo
CoreWeave's Q2 Sparks Massive Sell-Off -- Is This the Buy-the-Dip Moment?
Aug 14 - CoreWeave CRWV) posted Q2 results after the bell, delivering a mixed bag that rattled the stock in pre-market trading. Revenue came in at $1.21 billion, well ahead of the $1.08 billion forecast and more than triple last year's $395.4 million. But a larger-than-expected loss per share, $0.60 versus Wall Street's expected $0.52, took some shine off the top-line beat. Warning! GuruFocus has detected 5 Warning Signs with NVDA. The market reaction was swift. Shares plunged about 20% on Wednesday's trading. CoreWeave's IPO lock-up period is expiring on Friday, freeing up 83% of Class A shares and potentially adding selling pressure. While the red ink isn't new for the GPU cloud provider, the company's premium valuation leaves little margin for disappointment. CoreWeave trades at a forward EV/Sales multiple of 15.69x, more than 400% above the sector median. Heavy spending is part of the model, with Q2 CapEx at $2.9 billion and full-year guidance unchanged at $2023 billion. On the positive side, adjusted EBITDA and operating income beat expectations, and the revenue backlog jumped 86% year-over-year to $30.1 billion, thanks in part to a $4 billion deal with OpenAI. Microsoft (NASDAQ:MSFT) and Meta Platforms (NASDAQ:META) remain the largest customers, while partnerships with Nvidia (NASDAQ:NVDA), IBM (NYSE:IBM), and Applied Digital (APLD) keep CoreWeave plugged into the AI infrastructure boom. Given the volatility, some see opportunity. A dip-buying strategy could play out in two phases, after the earnings-driven drop, and again if Friday's lock-up expiry sparks further weakness. For risk-tolerant investors, the long-term AI demand story remains intact, but patience will be required. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20 minutes ago
- Yahoo
Why the Google Antitrust Ruling Could Deal a Blow to Apple's Profits
Key Points Apple stock is surging on tariff-related news right now, but an upcoming legal ruling could bode badly for the "Magnificent Seven" company. This month, Apple could lose an important source of revenue from the fallout of the ruling. The potential revenue loss likely isn't factored into Apple's current valuation. 10 stocks we like better than Apple › Apple (NASDAQ: AAPL) shares have been trending higher lately due to news that has assuaged investor concerns about the impact of recent tariff hikes on profitability. However, there's another possible risk to Apple's future profitability that few are talking about: the Google antitrust ruling. Make no mistake: The judge's ruling could negatively affect Google's search market dominance. In turn, this could be bad news for shares in Google's parent company, Alphabet (NASDAQ: GOOG)(NASDAQ: GOOGL). Then again, at least for Alphabet, alongside these potential negative consequences is the potential for the judge's decision to serve as a catalyst for Alphabet stock in the coming years. Unfortunately, there's no such silver lining for Apple. Instead, the iPhone maker faces the prospect of losing some or all of a key revenue source. Following the judge's decision, if this risk becomes more apparent, it could lead to a new round of volatility for Apple stock. The Google antitrust ruling, potential remedies, and an impending final decision Back in 2020, the U.S. Department of Justice (DOJ) filed a civil suit against Alphabet's Google subsidiary. The suit alleged that some of Google's practices, such as search engine exclusivity agreements with device makers such as Apple, were monopolistic and anticompetitive. This suit, known as United States v. Google LLC (2020), went to trial in September 2023, and in August 2024, Judge Amit Mehta ruled in the DOJ's favor. Post-verdict, both the DOJ and Google submitted proposed remedies to address Google's practices deemed anticompetitive. These proposals were presented in a separate remedies case held last spring. The DOJ's proposal called for some pretty severe remedies, including an end to Google's search exclusivity deal with Apple, as well as divestitures of Google's Chrome browser and Android mobile operating system businesses. Google, on the other hand, has proposed milder remedies. For instance, changes such as allowing customers to choose whether to make Google the default search engine on a device. This month, Judge Mehta is expected to issue his final ruling on the remedies. If he rules in favor of a search exclusivity ban, such news could lead to a big drop in Apple's annual earnings. Why the final ruling could reduce Apple's profits by double digits As discussed earlier, there may be a silver lining in all of this for Alphabet. Even a ruling that calls for a divestiture of Chrome and Android could bode well for Alphabet stock in the long term. As analysts at D.A. Davidson recently argued, a breakup of Alphabet into separate companies could unlock significant value. Per the analysts, Alphabet's breakup value could be as much as $304 per share. That represents a more than 54% premium to the current GOOG stock price. On the other hand, Apple could lose a little or a lot from this pending decision. According to J.P. Morgan analyst Samik Chatterjee, Google pays Apple around $28 billion per year for search traffic generated from Apple devices. Of that figure, around $12.5 billion comes from U.S.-based customers. These payments likely have a nearly 100% gross margin. Over the past 12 months, Apple has had an effective income tax rate of around 24%. This suggests that if the judge's decision includes an end to the search exclusivity deal, this would reduce Apple's annual earnings by $9.5 billion, or around 12%. The impact of this wouldn't be immediate. Google is likely to appeal the judge's remedy decision. Still, based on Apple's current valuation, the market currently assumes Apple's Google search revenue stream is not under threat. If this changes, it could lead to volatility for shares. What This Means for Apple Stock in the Near-Term Currently, Apple stock trades for around 31 times forward earnings. Although this valuation may seem reasonable relative to similar "Magnificent Seven" stocks, like Meta Platforms (NASDAQ: META) and Microsoft (NASDAQ: MSFT), in my view, Apple is overvalued, given the risks. Why? Historically, Apple has traded for between 25 and 30 times earnings. At today's higher valuation, investors are likely expecting factors like Apple's recent increase in its artificial intelligence (AI) infrastructure investments to drive higher earnings growth going forward. However, the impact of an end to Apple's search exclusivity agreement with Google could counter the benefit of its AI-related growth. Even if the judge accepts Google's milder remedy proposal, this may still lead to a reduction of Apple's Google search revenue, which would still likely affect overall earnings growth. If the judge's decision suggests any future impact on this key revenue stream, the market could react negatively, so I'm sticking to the sidelines for now. Should you invest $1,000 in Apple right now? Before you buy stock in Apple, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Apple wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $649,544!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,113,059!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 The Motley Fool has positions in and recommends Alphabet, Apple, Meta Platforms, and Microsoft. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. Thomas Niel has no position in any of the stocks mentioned. Why the Google Antitrust Ruling Could Deal a Blow to Apple's Profits was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
